{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:01:59Z","timestamp":1787068919470,"version":"build-2736575974"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:00:00Z","timestamp":1675728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["NCC201711018"],"award-info":[{"award-number":["NCC201711018"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["NCT03507166"],"award-info":[{"award-number":["NCT03507166"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2409902"],"award-info":[{"award-number":["2022YFC2409902"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013290","name":"National Key Research and Development Program of China Stem Cell and Translational Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013290","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the National Cancer Center"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.jncc.2023.02.003","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T18:20:38Z","timestamp":1677694838000},"page":"121-128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancer"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6249-5147","authenticated-orcid":false,"given":"Huizi","family":"Lei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xieqiao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxia","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benkang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhisong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqing","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changlu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanliang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinan","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jncc.2023.02.003_bib0001","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1056\/NEJMp058197","article-title":"The distinctive nature of HER2-positive breast cancers","volume":"353","author":"Burstein","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jncc.2023.02.003_bib0002","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/852748","article-title":"Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: overexpression and Therapeutic Implications","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Mol Biol Int"},{"key":"10.1016\/j.jncc.2023.02.003_bib0003","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.3390\/cancers12113345","article-title":"Assessment of HER2 Protein Overexpression and Gene Amplification in Renal Collecting Duct Carcinoma: therapeutic Implication","volume":"12","author":"Costantini","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jncc.2023.02.003_bib0004","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10555-015-9552-6","article-title":"HER2 expression status in diverse cancers: review of results from 37,992 patients","volume":"34","author":"Yan","year":"2015","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.jncc.2023.02.003_bib0005","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jncc.2023.02.003_bib0006","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/MOU.0000000000000676","article-title":"The landscape of immunotherapy in metastatic urothelial carcinoma","volume":"29","author":"Teo","year":"2019","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.jncc.2023.02.003_bib0007","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.euf.2021.01.003","article-title":"Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: a Systematic Review and Meta-analysis","volume":"8","author":"Rizzo","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.jncc.2023.02.003_bib0008","doi-asserted-by":"crossref","first-page":"739","DOI":"10.2217\/fon-2021-0841","article-title":"Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: a meta-analysis","volume":"18","author":"Rizzo","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.jncc.2023.02.003_bib0009","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1080\/14737140.2020.1807334","article-title":"Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors","volume":"20","author":"Mollica","year":"2020","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.jncc.2023.02.003_bib0010","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jncc.2023.02.003_bib0011","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejca.2014.10.009","article-title":"Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2","volume":"51","author":"Oudard","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jncc.2023.02.003_bib0012","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1200\/JCO.2015.66.3468","article-title":"Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1\/2-Positive Metastatic Bladder Cancer","volume":"35","author":"Powles","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jncc.2023.02.003_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102351","article-title":"The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: a systematic review and future perspectives","volume":"104","author":"Patelli","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jncc.2023.02.003_bib0014","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jncc.2023.02.003_bib0015","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jncc.2023.02.003_bib0016","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.juro.2015.05.087","article-title":"Targeting HER2 with T-DM1, an Antibody cytotoxic drug conjugate, is effective in HER2 over expressing bladder cancer","volume":"194","author":"Hayashi","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.jncc.2023.02.003_bib0017","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","article-title":"Open-label, multicenter, phase ii study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Sheng","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jncc.2023.02.003_bib0018","article-title":"Ulbright. 2016 World health organization classification of urinary system and male genital organs","author":"Holger Moch","year":"2016","journal-title":"IARC: Lyon"},{"key":"10.1016\/j.jncc.2023.02.003_bib0019","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5858\/arpa.2013-0953-SA","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"138","author":"Wolff","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jncc.2023.02.003_bib0020","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of American Pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jncc.2023.02.003_bib0021","doi-asserted-by":"crossref","first-page":"38372","DOI":"10.18632\/oncotarget.5368","article-title":"Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens","volume":"6","author":"Ahn","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jncc.2023.02.003_bib0022","first-page":"2440","article-title":"Her-2\/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors","volume":"7","author":"Jimenez","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jncc.2023.02.003_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.653491","article-title":"The clinical significance and prognostic value of HER2 expression in bladder cancer: a meta-analysis and a bioinformatic analysis","volume":"11","author":"Gan","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jncc.2023.02.003_bib0024","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/ajcp\/aqab083","article-title":"Reappraisal of HER2 amplification in high-grade urothelial carcinoma based on 2018 ASCO\/CAP clinical practice guidelines","volume":"156","author":"Mohanty","year":"2021","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jncc.2023.02.003_bib0025","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2559.2008.03028.x","article-title":"Assessment of a HER2 scoring system for gastric cancer: results from a validation study","volume":"52","author":"Hofmann","year":"2008","journal-title":"Histopathology"},{"key":"10.1016\/j.jncc.2023.02.003_bib0026","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/modpathol.2015.98","article-title":"Assessment of a HER2 scoring system for colorectal cancer: results from a validation study","volume":"28","author":"Valtorta","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jncc.2023.02.003_bib0027","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1038\/s41379-018-0023-9","article-title":"Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility","volume":"31","author":"Moktefi","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jncc.2023.02.003_bib0028","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1038\/modpathol.2015.112","article-title":"Impact of updated HER2 testing guidelines in breast cancer\u2013re-evaluation of HERA trial fluorescence in situ hybridization data","volume":"28","author":"Stoss","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jncc.2023.02.003_bib0029","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/sj.bjc.6601245","article-title":"HER2\/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder","volume":"89","author":"Latif","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jncc.2023.02.003_bib0030","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jncc.2023.02.003_bib0031","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jncc.2023.02.003_bib0032","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/bju.15006","article-title":"Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertions","volume":"125","author":"Madison","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.jncc.2023.02.003_bib0033","doi-asserted-by":"crossref","first-page":"9262","DOI":"10.18632\/oncotarget.24265","article-title":"Prognostic implications of HER2 heterogeneity in gastric cancer","volume":"9","author":"Motoshima","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.jncc.2023.02.003_bib0034","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/modpathol.2012.36","article-title":"Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance","volume":"25","author":"Seol","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jncc.2023.02.003_bib0035","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.humpath.2018.05.022","article-title":"Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype","volume":"80","author":"Zinnall","year":"2018","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jncc.2023.02.003_bib0036","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/8463731","article-title":"HER2 protein overexpression and gene amplification in plasmacytoid urothelial carcinoma of the urinary bladder","volume":"2016","author":"Kim","year":"2016","journal-title":"Dis Markers"},{"key":"10.1016\/j.jncc.2023.02.003_bib0037","doi-asserted-by":"crossref","first-page":"6856","DOI":"10.1038\/s41388-020-01465-y","article-title":"EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer","volume":"39","author":"Rose","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.jncc.2023.02.003_bib0038","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1186\/s12885-017-3520-1","article-title":"Squamous differentiation in patients with superficial bladder urothelial carcinoma is associated with high risk of recurrence and poor survival","volume":"17","author":"Li","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jncc.2023.02.003_bib0039","doi-asserted-by":"crossref","first-page":"6014","DOI":"10.3390\/cancers13236014","article-title":"Her2 expression in circulating tumor cells is associated with poor outcomes in patients with metastatic castration-resistant prostate cancer","volume":"13","author":"Maillet","year":"2021","journal-title":"Cancers"}],"container-title":["Journal of the National Cancer Center"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667005423000182?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667005423000182?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:36:16Z","timestamp":1763019376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667005423000182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S2667005423000182"],"URL":"https:\/\/doi.org\/10.1016\/j.jncc.2023.02.003","relation":{},"ISSN":["2667-0054"],"issn-type":[{"value":"2667-0054","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of the National Cancer Center","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jncc.2023.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Chinese National Cancer Center. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}